Entering text into the input field will update the search result below

Ascendis Pharma's TransCon Growth Hormone shows positive results in mid-stage study; shares up 17% premarket

Jul. 30, 2015 9:20 AM ETAscendis Pharma A/S (ASND) StockBy: Douglas W. House, SA News Editor
  • Thinly traded Ascendis Pharma (ASND) jumps 17% premarket on increased volume in response to its announcement of top-line results from a six-month Phase 2 clinical trial evaluating once-weekly TransCon Growth Hormone in 53 treatment-naive pre-pubertal children with growth hormone deficiency (GHD).
  • The data show mean annualized height velocities for two doses of TransCon of 11.9 cm (0.14 mg/kg) and 13.9 cm (0.30 mg/kg). The results were comparable to the 11.6 cm demonstrated with daily injections of Pfizer's (PFEGenotropin (somatropin [rDNA origin] for injection) at a comparative dose of 0.21 mg/kg/week.
  • The company intends to release the full data set at the annual meeting of the European Society for Paediatric Endocrinology in October. A 12-month, parallel- group Phase 3 trial comparing TransCon to daily injections of growth hormone is expected to commence in mid-2016.

Recommended For You

More Trending News

About ASND Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ASND--
Ascendis Pharma A/S